Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 183 matching trials from the live ClinicalTrials.gov search.
Recruiting Not applicable Interventional

Emotional Awareness Therapy Study

NCT07624825
Conditions
Traumatic Brain Injury
Interventions
TREAT-A, TREAT-B
Behavioral
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Edison, New Jersey
Conditions
Traumatic Injury, Muscle Injury, Tendon Injury, Soft Tissue Injury, Extremity Injury
Interventions
Extracellular Matrix
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Spinal Cord Injury, Muscle Spasticity
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Long Beach, California • Sacramento, California + 23 more
Conditions
Traumatic Brain Injury
Interventions
Angiotensin (1-7), Sterile saline
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Cerebral Palsy, Traumatic Brain Injury, Metabolic Disease, Hypotonia
Interventions
customized posture support
Device
Lead sponsor
University of Hartford
Other
Eligibility
3 Months to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Cheshire, Connecticut • Hartford, Connecticut • Wethersfield, Connecticut
Terminated Not applicable Interventional Results available

Enhanced Bioscaffold for Volumetric Muscle Loss

NCT04051242
Conditions
Muscle Loss
Interventions
XenMatrix™ AB Surgical Graft
Device
Lead sponsor
J. Peter Rubin, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Peripheral Nerve Injuries
Interventions
Autologous Human Schwann Cells
Biological
Lead sponsor
W. Dalton Dietrich
Other
Eligibility
16 Years to 16 Years · Female only
U.S. locations
1
States / cities
Miami, Florida
Conditions
Intracranial Hypertension
Interventions
HS-1000 recording
Device
Lead sponsor
HeadSense Medical
Industry
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Akron, Ohio
Conditions
Respiratory Failure, Traumatic Brain Injury
Interventions
Early tracheostomy, Late tracheostomy
Procedure
Lead sponsor
Memorial Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Johnstown, Pennsylvania
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Trifecta Research Study

NCT07717866
Conditions
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder, Suicidal Ideation
Interventions
Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine, Physiological Supplementation
Device · Drug
Lead sponsor
Axial Therapeutic Research
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Northridge, California
Completed Not applicable Interventional Results available

Clinical Trial to Improve the Magnetic Levator Prosthesis

NCT03818204
Conditions
Blepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke, Traumatic Brain Injury
Interventions
Magnetic Levator Prosthesis (MLP)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
4 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Peripheral Nerve Injury
Interventions
Autologous Human Schwann Cell
Biological
Lead sponsor
W. Dalton Dietrich
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Miami, Florida
Conditions
Major Depressive Disorder, Dysthymia, Spinal Cord Injuries
Interventions
venlafaxine XR, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 64 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 3 more
Conditions
Pain, Opiate
Interventions
sufentanil
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Traumatic Brain Injury (TBI)
Interventions
Not listed
Lead sponsor
Advanced Brain Monitoring, Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Severe Neuropathic Pain Due to Radiculopathy or Radicular Injury, Spinal Cord Injuries, Phantom Limb Pain
Interventions
Experimental: ExAblate Transcranial treatment
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Brain Injury
Interventions
Polypharmacy using FDA-approved products, Median Nerve Stimulation (MNS), Nutraceutical Supplementation, Standard of Care
Drug · Device · Dietary Supplement + 1 more
Lead sponsor
International Brain Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Edison, New Jersey
Conditions
Consciousness Disorders, Disorders of Consciousness Due to Severe Brain Injury
Interventions
Low-intensity focused ultrasound
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Conditions
Pain, Cancer, Sickle Cell Anemia, Severe Burns
Interventions
ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])
Drug
Lead sponsor
Cephalon
Industry
Eligibility
3 Years to 15 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
26
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 21 more
Conditions
Traumatic Brain Injury
Interventions
SLV334, Placebo
Drug
Lead sponsor
Abbott Products
Industry
Eligibility
16 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Baltimore, Maryland • Dayton, Ohio • Portland, Oregon + 1 more
Recruiting No phase listed Observational

Predict Severe Traumatic Brain Injury

NCT06966713
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Validation of Brain Function Assessment Algorithm for mTBI/Concussion

NCT03671083
Conditions
Brain Injuries, Traumatic, Concussion, Mild, Concussion, Severe, Concussion, Intermediate, Concussion, Brain
Interventions
BrainScope Ahead 300iP
Device
Lead sponsor
BrainScope Company, Inc.
Industry
Eligibility
13 Years to 25 Years
Enrollment
309 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Fayetteville, Arkansas • Miami, Florida • East Lansing, Michigan + 2 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Early Check: Expanded Screening in Newborns

NCT03655223
Conditions
Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy, Hyperinsulinemic Hypoglycemia, Familial 1, Diabetes Mellitus, Adrenoleukodystrophy, Neonatal, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Very Long Chain Acyl Coa Dehydrogenase Deficiency, Beta-ketothiolase Deficiency, Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency, Primary Hyperoxaluria Type 1, Congenital Bile Acid Synthesis Defect Type 2, Pyridoxine-Dependent Epilepsy, Hereditary Fructose Intolerance, Hypophosphatasia, Hyperargininemia, Mucopolysaccharidosis Type 6, Argininosuccinic Aciduria, Citrullinemia, Type I, Wilson Disease, Maple Syrup Urine Disease, Type 1A, Maple Syrup Urine Disease, Type 1B, Biotinidase Deficiency, Neonatal Severe Primary Hyperparathyroidism, Intrinsic Factor Deficiency, Usher Syndrome Type 1D/F Digenic (Diagnosis), Cystic Fibrosis, Stickler Syndrome Type 2, Stickler Syndrome Type 1, Alport Syndrome, Autosomal Recessive, Alport Syndrome, X-Linked, Carbamoyl Phosphate Synthetase I Deficiency Disease, Carnitine Palmitoyl Transferase 1A Deficiency, Carnitine Palmitoyltransferase II Deficiency, Cystinosis, Chronic Granulomatous Disease, Cerebrotendinous Xanthomatoses, Maple Syrup Urine Disease, Type 2, Severe Combined Immunodeficiency Due to DCLRE1C Deficiency, Thyroid Dyshormonogenesis 6, Thyroid Dyshormonogenesis 5, Supravalvar Aortic Stenosis, Factor X Deficiency, Hemophilia A, Hemophilia B, Tyrosinemia, Type I, Fructose 1,6 Bisphosphatase Deficiency, Glycogen Storage Disease Type I, G6PD Deficiency, Glycogen Storage Disease II, Galactokinase Deficiency, Mucopolysaccharidosis Type IV A, Galactosemias, Guanidinoacetate Methyltransferase Deficiency, Agat Deficiency, Glutaryl-CoA Dehydrogenase Deficiency, Gtp Cyclohydrolase I Deficiency, Hyperinsulinism-Hyperammonemia Syndrome, Primary Hyperoxaluria Type 2, 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Mitochondrial Trifunctional Protein Deficiency, Sickle Cell Disease, Beta-Thalassemia, Holocarboxylase Synthetase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria, Primary Hyperoxaluria Type 3, Hermansky-Pudlak Syndrome 1, Hermansky-Pudlak Syndrome 4, Apparent Mineralocorticoid Excess, HSDB, CBAS1, Mucopolysaccharidosis Type 2, Mucopolysaccharidosis Type 1, Severe Combined Immunodeficiency, X Linked, Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency, Diabetes Mellitus, Permanent Neonatal, Isovaleric Acidemia, Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder), Jervell and Lange-Nielsen Syndrome 2, Hyperinsulinemic Hypoglycemia, Familial, 2, Diabetes Mellitus, Permanent Neonatal, With Neurologic Features, Jervell and Lange-Nielsen Syndrome 1, Lysosomal Acid Lipase Deficiency, CblF, 3-Methylcrotonyl CoA Carboxylase 1 Deficiency, 3-Methylcrotonyl CoA Carboxylase 2 Deficiency, Waardenburg Syndrome Type 2A, Methylmalonic Aciduria cblA Type, Methylmalonic Aciduria cblB Type, Methylmalonic Aciduria and Homocystinuria Type cblC, MAHCD, Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency, Congenital Disorder of Glycosylation Type 1B, Mthfr Deficiency, Methylcobalamin Deficiency Type Cbl G (Disorder), Methylcobalamin Deficiency Type cblE, Usher Syndrome, Type 1B, N-acetylglutamate Synthase Deficiency, Ornithine Transcarbamylase Deficiency, Phenylketonurias, Waardenburg Syndrome Type 1, Congenital Hypothyroidism, Propionic Acidemia, Usher Syndrome, Type 1F, Pancreatic Agenesis 1, Hereditary Hypophosphatemic Rickets, Glycogen Storage Disease IXB, Glycogen Storage Disease IXC, MOWS, Epilepsy, Early-Onset, Vitamin B6-Dependent, Pyridoxal Phosphate-Responsive Seizures, Pituitary Hormone Deficiency, Combined, 1, Ptsd, Dihydropteridine Reductase Deficiency, Severe Combined Immunodeficiency Due to RAG1 Deficiency, Severe Combined Immunodeficiency Due to RAG2 Deficiency, Retinoblastoma, Multiple Endocrine Neoplasia Type 2B, Pseudohypoaldosteronism, Type I, Liddle Syndrome, Biotin-Responsive Basal Ganglia Disease, SCD, DIAR1, GSD1C, Acrodermatitis Enteropathica, Thyroid Dyshormonogenesis 1, Riboflavin Transporter Deficiency, Waardenburg Syndrome, Type 2E, SRD, Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency, Barth Syndrome, Adrenocorticotropic Hormone Deficiency, Transcobalamin II Deficiency, Thyroid Dyshormonogenesis 3, Segawa Syndrome, Autosomal Recessive, Autosomal Recessive Nonsyndromic Hearing Loss, Thyroid Dyshormonogenesis 2A, Congenital Isolated Thyroid Stimulating Hormone Deficiency, Hypothyroidism Due to TSH Receptor Mutations, Usher Syndrome Type 1C, Usher Syndrome Type 1G (Diagnosis), Von Willebrand Disease, Type 3, Combined Immunodeficiency Due to ZAP70 Deficiency, Adenine Phosphoribosyltransferase Deficiency, Metachromatic Leukodystrophy, Canavan Disease, Menkes Disease, Carbonic Anhydrase VA Deficiency, Developmental and Epileptic Encephalopathy 2, 17 Alpha-Hydroxylase Deficiency, Smith-Lemli-Opitz Syndrome, Krabbe Disease, Glutathione Synthetase Deficiency, Mucopolysaccharidosis Type 7, Rett Syndrome, Molybdenum Cofactor Deficiency, Type A, Niemann-Pick Disease, Type C1, Niemann-Pick Disease Type C2, Ornithine Aminotransferase Deficiency, 3-Phosphoglycerate Dehydrogenase Deficiency, Leber Congenital Amaurosis 2, Dravet Syndrome, Mucopolysaccharidosis Type 3 A, Ornithine Translocase Deficiency, Carnitine-acylcarnitine Translocase Deficiency, Glucose Transporter Type 1 Deficiency Syndrome, Creatine Transporter Deficiency, Niemann-Pick Disease Type A, Pitt Hopkins Syndrome, Tuberous Sclerosis 1, Tuberous Sclerosis 2, Ataxia With Isolated Vitamin E Deficiency, Angelman Syndrome, Prader-Willi Syndrome, Homocystinuria, Permanent Neonatal Diabetes Mellitus, Transient Neonatal Diabetes Mellitus, Factor VII Deficiency, Glycogen Storage Disease Type IXA1, Glycogen Storage Disease, Type IXA2, Glycogen Storage Disease IC, Glycogen Storage Disease Type IB, Central Hypoventilation Syndrome With or Without Hirschsprung Disease
Interventions
Confirmatory Testing
Diagnostic Test
Lead sponsor
RTI International
Other
Eligibility
1 Day to 31 Days
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Completed No phase listed Observational Accepts healthy volunteers

Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

NCT05945784
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute, Traumatic Brain Injury, SCI - Spinal Cord Injury, Ehlers-Danlos Syndromes (EDS), Lupus Erythematosus, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Graves Disease, Muscular Dystrophies
Interventions
Use of Rare Beauty makeup products
Other
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Pomona, California